Patent Application
20110183364
This invention lies within the technical field of the identification and detection of the hepatitis C virus (HCV).
More specifically, this invention provides an improved analytical method and its corresponding diagnosis kit for the detection of said virus C, which is especially useful in the identification and detection of the so-called “latent HCV infections”, which cannot be detected in serum or plasma samples using current standard analytical methods.
HCV is a member of the Hepacivirus genus within the Flaviviridae family of animal viruses. The HCV genome (hereinafter HCV-RNA) consists in a single-stranded RNA molecule of positive polarity that is about 9.4 kilobases (kb) long. It is assumed that HCV replication occurs via the synthesis of a negative-strand RNA chain, that is, a chain which is complementary to the molecule of genomic RNA of the virus which, in turn, acts as a mould for the synthesis of new molecules of the genomic RNA. Although the liver is the main target organ for HCV infection, this virus may, potentially, infect any type of cell, tissue or organ in the human body.
Currently there are techniques that allow without difficulty diagnosing HCV infections in a patient by detecting antibodies against HCV antigens (hereinafter anti-HCV) or HCV-RNA in serum or plasma samples.
However, there is a type of HCV infection that has been recently described, characterised in that it is “serologically silent”, wherein infected patients do not produce positive results in anti-HCV or HCV-RNA commercial detection kits in serum or plasma (hereinafter latent infection).
The general profile for this type of patients is people with anomalous results in hepatic function tests for an extended period of time, meaning abnormally high levels of hepatic enzymes. All or most of the known causes of liver disease have been assessed in these patients, which have been all ruled out based on either analytical, clinical or epidemiological data, for example: infection by hepatitis B virus (patients were negative to serum hepatitis B surface antigen and HBV-DNA), HCV (patients were negative to serum anti-HCV and HCV-RNA), chronic autoimmune hepatitis, alcoholic hepatitis, Gilbert's syndrome, biliary cirrhosis, as well as autoimmune, metabolic and genetic disorders, along with risk factors of liver damage such as consumption of alcohol, drugs, pharmaceutical products, transfusions, tattoos, body piercings, careless sexual behaviour, etc.
We are therefore dealing with a population with altered hepatic function which current analytical methods cannot explain, and the cause of which may be a latent infection by a certain form of the hepatitis C virus. Since this infection is impossible to diagnose rapidly, effectively and safely by current methods, this type of infection has two very important consequences:
Within this technical field, researchers use immunoassays as a usual laboratory test due to the reliability of its results. Enzyme immunoassay (EIA), in particular, is a commonly used test since it is a simple, reproducible, objective method that allows processing a large amount of body fluid samples in a short time, which facilitates its implementation in less complex laboratories.
There are currently existing commercial immunoassays for determining anti-HCV in blood. These EIA detect antibodies against the structural (core and envelope) and non-structural (NS) proteins of HCV. On the other hand, the sensitivity of commercial EIAs for determining anti-HCV in blood differ according to which HCV antigens are coating the solid phase, whether these are individual or fused proteins or peptide fragments.
Commercial EIAs for the detection of anti-HCV in human serum or plasma comprise the following active ingredients:
The technical field of action of the commercial EIA method for detecting anti-HCV is the “classic” infection by HCV. These EIA, called EIA screening, that are used to screen a population sample of individuals that might have been in contact with the HCV, show a proven effectiveness or 99% or more regarding their specificity and an analytical sensitivity that is close to 100% in patients with classic HCV infection.
The specificity of the commercial EIA method decreases in immunocompetent groups of subjects, such as volunteer blood donors, health professionals, prison workers or military personnel. Similarly, their sensitivity is lower in immunocompromised individuals [information from the Centre for Disease Control and Prevention of Atlanta, USA, according to its publication: Morbidity and Mortality Weekly Report 2003; 52 (No. RR-3):1-13].
Although the immunoassay technique already has a very well established protocol, any specialist in the field should be aware that the specific determination of each specific antigen or antibody requires a certain research effort in order to find suitable working conditions and reagents for each case. As a reference of the former we provide a list of publications that use the EIA method to determine anti-HCV.
Specifically, publications (5), (6), (7), (8), (9), (10) and (16) from the list refer to the use of the core antigen in anti-HCV determination in different clinical situations of classic HCV infection. As can be observed in these publications, core protein or peptides of different sizes have been used to detect anti-core HCV antibodies.
As an example, reference (5) describes the use of a synthetic core peptide (5-23) that allows detecting anti-HCV using EIA.
Publications (6) and (7) and other related publications carry out an analysis of the antigen regions of the HCV core protein (comprising amino acids 1 to 190) to identify immunodominant regions using synthetic peptides that allow characterising the immune response in “classic” infection by HCV. Specifically: 1) a peptide is identified that comprises amino acids 1-17 of the amino terminal of the core protein; 2) the main antigenic region in the sequence of amino acids 9-16 is located; 3) anti-HCV IgG antibodies are detected by EIA using a core peptide in 83% of sera from patients with anti-HCV detectable with commercial EIA kits.
On the other hand, reference (16) and other related publications describe both the use of synthetic core protein peptides with genotype 1a and that of HCV antigens to detect anti-HCV. The use of HCV core peptides with sequences of amino acids 1-18, 10-24, 11-28 1-30, 10-43 and others produced different percentages of detection of anti-HCV by EIA. As an example, the percentage of detection of anti-HCV in the sera of patients with classic infection by HCV genotype 1 (with positive anti-HCV results by commercial EIA) using each peptide was: 78% with core 1-18; 89% with core 10-24; 85% with core 11-28; 93% with core 1-30; 100% with core 10-43. This publication does not provide data on the determination of anti-core antibodies in subjects negative to anti-HCV using commercial EIA.
The research team that has developed this invention has been using immunoassay in recent years for their determinations of HCV both in blood (serum or plasma) and in the supernatants of human cell cultures. It has used immunoassay for analytical determinations of HCV in serum or plasma samples and in samples of the supernatant of cell cultures with results described in the following references:
Although commercial EIA can detect anti-HCV in “classic” infection by HCV, they do not work (that is, they produce a NEGATIVE result) with the “latent” variety of the disease. Commercial EIAs may not be sufficiently sensitive to detect trace amounts of anti-HCV. The reason they may not work correctly is that the mixture of antigens coating the solid phase may interfere and prevent the detection of trace amounts of anti-HCV.
In order to solve these problems we have tried some modifications or alternative applications. Thus, we determined the presence of anti-HCV using the MONOLISA® HCV Ag-Ab ULTRA assay (Bio-Rad Laboratories, Marnes-la-Coquette, France) in serum samples from patients diagnosed with latent infection by HCV (negative anti-HCV results with commercial EIAs: Ortho HCV 3.0 ELISA, Ortho Diagnostic Systems, Raritan, N.J., USA; and INNOTEST HCV Ab IV, Innogenetics, Gante, Belgium). The MONOLISA® HCV Ag-Ab ULTRA assay was only capable of detecting the presence of anti-VHC in the serum of 1 patient with latent infection by HCV [Quiroga J A, et al. J Clin Microbial 2006; 44:4559-4560].
This data shows that the alternatives for anti-HCV detection do not work.
From the above it can be deduced that there is a need for a fast, safe and effective method to determine the existence of latent HCV infection in a subject suspected of infection. The gold standard method for identifying latent HCV infection is HCV-RNA detection from a biopsy of liver tissue.
In this regard, Spanish Patent No. 200303050 describes an analytical method based on in situ hybridisation that detects HCV-RNA in liver tissue, and therefore identifies latent HCV infection that cannot be detected in serum or plasma samples using standard analytical methods.
Nevertheless, biopsies are invasive methods that are cannot always be performed since they involve risks for the patients. Therefore, a simple and sensitive method is required to diagnose latent HCV infection from blood samples.
Researchers have intensified the search for the determining parameters of the immunoassay protocol (e.g., method of preparation of the reaction matrix, pretreatment of samples prior to the immunochemistry reaction, type and strength of the conjugate antiserum, time necessary for the immunochemistry reaction to occur, etc.) for diagnosing a potential latent HCV infection.
This invention, as described in the title, relates to a improved analytical method for the detection of latent hepatitis C, the applications of this analytical method and its corresponding diagnostic kit.
Specifically, it relates to a screening immunoassay test. A preferred embodiment of the above is an immunoassay chosen from ELISA, radioimmunoassay, or a fluorescence, chemiluminescence or bioluminescence immunoassay.
Said screening immunoassay for detecting latent hepatitis C uses serum or plasma samples from peripheral blood or from organs or fluids produced or secreted by isolated cells, or secretions from tissues or organs, or blood or fluids from organs.
A preferred embodiment of the invention consists of a screening immunoassay for detecting latent hepatitis C that uses the peptide of the HCV core protein corresponding to the sequence with SEQ.ID.NO:1.
A particular embodiment uses, as well as SEQ.ID.NO:1, an additional sequence corresponding to SEQ.ID.NO:2.
A particular embodiment uses, as well as SEQ.ID.NO:1, an additional sequence corresponding to SEQ.ID.NO:3.
A particular embodiment uses, as well as SEQ.ID.NO:1, the two additional sequences SEQ.ID.NO:2 and SEQ.ID.NO:3.
The preferred immunoassay of the invention is an ELISA using as an antigen the peptide represented by SEQ.ID.NO:1, the combination of the two sequences SEQ.ID.NO:1 and SEQ.ID.NO:2, the combination of the two sequences SEQ.ID.NO:1 and SEQ.ID.NO:3 and the combination of the three sequences: SEQ.ID.NO:1, SEQ.ID.NO:2 and SEQ.ID.NO:3.
On the other hand, in other assays carried out by the researchers it was observed that other peptides of the core protein with a sequence of 20 amino acids other than that represented by SEQ.ID.NO:1 also showed antigen functionality. However, the sensitivity of anti-HCV detection was lower than using the 15 amino acid peptide of the preferred embodiment of the invention.
According to a preferred embodiment of the invention in which the screening immunoassay uses the peptide with sequence tag SEQ.ID.NO:2 as an antigen, anti-HCV IgG core is detected by EIA in the serum of 100% of patients with classic HCV infection of genotypes 1, 3 and 4 (with anti-HCV positive results using commercial EIA tests). The novel application also detects anti-HCV IgG core in the serum of 15% of patients with latent HCV infection.
According to a preferred embodiment of the invention in which the screening immunoassay uses the peptide with sequence tag SEQ.ID.NO:3 as an antigen, anti-HCV IgG core is detected by EIA in the serum of 75% of patients with classic HCV infection of genotypes 1, 3 and 4 (with anti-HCV positive results using commercial EIA tests). The novel application is that it also detects anti-HCV IgG core in the serum of 25% of patients with latent HCV infection.
So that the embodiment of the invention using the peptides with sequence tags SEQ.ID.NO:1, SEQ.ID.NO:2 and SEQ.ID.NO:3 detects anti-HCV IgG core by EIA in the serum 100% of patients with classic HCV infection with genotype 1, 3 or 4 (with positive anti-HCV results using commercial EIA tests). The novel application also detects anti-HCV IgG core in the serum of 50% of patients with latent HCV infection with genotype 1 (that is, with negative anti-HCV results using commercial EIA tests). It can therefore be said that the analytical method object of this invention increases the sensitivity of existing EIA tests, improves serological diagnosis and may be useful for tracing latent HCV infection.
Such that another preferred embodiment of the invention uses as an antigen for the screening immunoassay a peptide with sequence tag SEQ.ID.NO:1 and at least another peptide with the sequence of sequence tag SEQ.ID.NO:2 and/or SEQ.ID.NO:3.
This more preferred embodiment with the sequence with sequence tag SEQ.ID.NO:1 detects by EIA anti-HCV IgG core in the serum of 98% of patients with classic HCV infection with genotype 1 (with positive anti-HCV results using commercial EIA tests). The novel application is that it also detects anti-HCV IgG core in the serum of 40% of patients with latent HCV infection (that is, with negative anti-HCV results using commercial EIA tests). We can therefore say that the analytical method object of this invention increases the sensitivity of existing EIA tests, improves serological diagnosis and may be useful for tracing latent HCV infection.
Therefore, in other populations with potential risk of latent HCV infection anti-HCV IgG core is detected in the serum of 27% of the relatives of patients with latent HCV infection and 35% of relatives of patients with classic HCV infection who gave negative anti-HCV results using commercial EIA tests. That is, compared to commercial anti-HCV screening methods, the measurement of anti-HCV IgG core allows determining exposure to HCV, and its transmission between relatives of HCV-infected patients.
On the other hand, although no latent HCV infection has been described with a genotype other than genotype 1b, the method object of the invention is capable of detecting anti-HCV IgG core antibodies in the serum or plasma of patients with classic HCV infection with genotype 1 (wither 1b or 1a), as well as cases with genotypes other than genotype 1. The sequence with sequence tag SEQ.ID.NO:1 has some advantages regarding other longer sequences: When omitting positions 4 and 20 of the peptide's amino acid sequence, some variable positions are also excluded that are immediately before and after, present in genotypes 2b, 3, 4 and 6 (see
On the other hand, in other experiments carried out we observed that shorter peptides, with sequences of between 6 and 10 amino acids from the amine end of the core protein, showed antigen functionality. However, the sensitivity of anti-HCV detection was lower than using the 15 amino acid peptide of the preferred embodiment of the invention.
Such that another embodiment of the invention uses a peptide with at least 6 correlative amino acids from the NH-terminal of the peptide with sequence tag SEQ.ID.NO:1 as the antigen of the screening immunoassay.
According to the options found in the state of the art, this immunoassay can use an antiserum labelled with an isotopic or non-isotopic tracer. Amongst the latter, a preferred embodiment of the invention comprises the use of a fluorophore, a chromophore, an enzyme or any other molecule that produces a conjugate that is suitable for immunoassay tests. An even more preferred embodiment uses an anti-human IgG antibody conjugated with the horseradish peroxidase enzyme (anti-IgG-HRP).
The present invention also has as an object a diagnostic kit for the implementation of said analytical method for the detection of latent hepatitis C. Specifically, said kit comprises the essential components of the screening immunoassay to be performed, such as a Reaction matrix, Reagent, HCV, Stopping agent, Sample diluent, Washout solution, Conjugate solution and Reagents for developing the immunochemistry reaction.
Specifically, the screening immunoassay that can be performed with this kit is chosen from an ELISA, a radioimmunoassay, a fluorescence, chemiluminescence or bioluminescence immunoassay.
Said screening immunoassay contained in the kit for detecting latent hepatitis C uses serum or plasma samples from peripheral blood or from organs or fluids produced or secreted by isolated cells, or secretions from tissues or organs, or blood or fluids from organs.
A preferred embodiment of this diagnostic kit uses a peptide with a sequence corresponding to SEQ.ID.NO:1.
An additional particular embodiment uses, as well as SEQ.ID.NO:1, an additional sequence corresponding to SEQ.ID.NO:2.
An additional particular embodiment of this diagnostic kit uses, as well as SEQ.ID.NO:1, an additional sequence corresponding to SEQ.ID.NO:3.
An additional particular embodiment of this diagnostic kit uses, as well as SEQ.ID.NO:1, the two additional sequences corresponding to SEQ.ID.NO:2 and SEQ.ID.NO:3.
The analytical method of this invention based on immunoassays can be summarised in the diagram as follows:
Since the analytical method in this invention is especially intended for the detection of anti-HCV in latent infection, it is necessary to optimise the different stages of the general method for this specific case, in order to achieve the improved analytical method object of the present invention.
The immunochemistry reaction that solid-phase immunoassays are based on takes place in a reaction matrix or support that can be a microplate divided into small cells or wells for individual samples, tubes, spheres, strips or combinations thereof, of an organic material such as polystyrene, polyethylene, polyvinyl, polycarbonate, cellulose, etc.
The target molecules of the method are specific anti-HCV antibodies of the hepatitis C virus structural core protein. The samples containing these target molecules can be either serum or plasma samples. These samples will be taken from patients in whom no anti-HCV or HCV-RNA antibodies are detected in serum or plasma using available commercial methods, but who have sustained abnormal values of liver enzymes in their blood.
The samples are usually obtained from blood extracted from the patients.
The following examples illustrate the method of the invention without meaning to limit it in any way.
The serum or plasma samples are obtained by extracting 10 ml of venous blood using a suitable device and placing the blood in a glass tube of the Vacutainer® type (Beckton-Dikinson, Plymouth, UK) with gel on the bottom, designed to obtain serum, or containing anticoagulant (170 IU of lithium heparin) to obtain plasma. The blood is then centrifuged for 20 minutes at 1,200×g at ambient temperature (between 20 and 25° C.) in a 1.0R Heraeus Megafuge centrifuge (Heraeus, Osterode, Germany). The upper layer containing the serum or plasma is separated and approximately 1 ml of this is placed in a polystyrene tube with a cap, suitable for storing serum or plasma at −20° C. until use.
The reagent HCV used in the method object of the invention is a synthetic pentadecapeptide with the sequence of SEQ.ID.NO:1, comprising amino acids 5 to 19 of the N-terminal end of the HCV core protein (hereinafter, core peptide 5-19). Core peptide 5-19 was synthesised by GeneScript Corporation (Scotch Plains, N.J., USA). The lyophilised core peptide 5-19 contains 7 mg of protein with a purity of 93.8% according to analyses performed by high performance liquid chromatography and mass spectrometry. The lyophilised core peptide 5-19 is dissolved in ultra-pure H2O (Milli-Q; Millipore, Molsheim, France) to obtain a concentration of 1 mg/ml; it is divided into 220 μl aliquots in sterile 1 ml polypropylene tubes with caps and stored at a temperature of −20° C. until use.
The solid phase consists of a flat bottom, sterile, 96-well EIA polystyrene microtitre plate, without caps (Costar, Cambridge, Mass., USA). To prepare the reaction matrix, thaw an aliquot of the core peptide 5-19 of those described in Example 2 to 4° C. Prepare a reagent solution with a concentration of 10 μg/ml by mixing 110 μl of reconstituted core peptide 5-19 with 10.89 ml of 0.1 M buffered sodium carbonate solution at pH 9.6, pre-cooled to 4° C. Place 100 μl of the 10 μg/ml core peptide 5-19 solution in each well and incubate for 18 hours at a temperature of 4° C. without stirring in an S-1000-2 refrigerator (Azkoyen, Madrid, Spain) At the end of the incubation period wash each well twice with 200 μl of washout solution made from 0.1 M sodium phosphate buffer at pH 7.4 to which 0.05% of polyoxyethylene-(20)-sorbitan monolaurate (Tween-20®/Sigma Chemical Co., St. Louis, Mo., USA) has been added. When the last washout has finished, remove the excess washout solution by turning the plate upside down over absorbent paper. Then add 150 μl of the blocking agent made from 0.1 M buffered sodium and potassium phosphate solution at pH 7.4, supplemented with 10% of foetal bovine serum (Sera Laboratories International Ltd., West Sussex, UK), inactivated by heating at 56° C. for 30 minutes, to which 0.05% of Tween-20® is then added, incubating the whole at 37° C. for 60 minutes in a Heraeus I-42 incubator. Withdraw the excess blocking agent at the end of the incubation period by turning the plate upside down. Wash each well twice with 200 μl of washout solution. When the last washout has finished, remove the excess washout solution by turning the plate upside down over absorbent paper. At the end of this stage the reaction matrix will be ready for incubation with the samples.
This first option consists in performing simultaneous determination using SEQ.ID.NO:1, SEQ.ID.NO:2 and SEQ.ID.NO:3 separately to prepare the reaction matrix (Example 3 of the application). Such that “100 μl of the 10 μg/ml core peptide 5-19 solution are placed in each well and incubated for 18 hours at a temperature of 4° C. . . . ”; or “100 μl of the 10 μg/ml core peptide 21-40 solution are placed in each well and incubated for 18 hours at a temperature of 4° C. . . . ”; or “100 μl of the 10 μg/ml core peptide 101-120 solution are placed in each well and incubated for 18 hours at a temperature of 4° C. . . . ”. The plate wells can only be coated with one of the peptides, or using two peptides and coating half the plate wells with each peptide, or using the three peptides and coating a third of the plate wells with each peptide. The rest of the method is the same.”
This second option consists in carrying out the invention by combining the peptides with sequence tags SEQ.ID.NO:1, SEQ.ID.NO:2 and SEQ.ID.NO:3 to prepare the reaction matrix (Example 3 of the application). Such that 100 μl of a mixed solution of the two peptides with sequences corresponding to SEQ.ID.NO:1 and SEQ.ID.NO:2, a mixed solution of SEQ.ID.NO:1 and SEQ.ID.NO:3, or a mixed solution of SEQ.ID.NO:1, SEQ.ID.NO:2 and SEQ.ID.NO:3 are placed in the plate wells, that is, for example, “100 μl of a mixed solution of the 10 μg/ml core peptide 5-19 and the 10 μg/ml core peptide 101-120 solution are placed in each well and incubated for 18 hours at a temperature of 4° C. . . . ”, etc. The rest of the method is the same.
The serum or plasma sample is thawed from −20° C. to ambient temperature (between 20 and 25° C.), repeatedly turning the tube to homogenise its contents before pretreatment. This pretreatment is a crucial stage in the method object of the invention, a step that is not specified in the protocols of most commercial EIA tests. This consists in an incubation the purpose of which is to adsorb the sample components in order to eliminate the non-specific antigen-antibody bonds that might conceal trace amounts of anti-HCV. 50 μl of serum or plasma sample are placed in a 1.5 ml polypropylene microtube (Sarsted, Nümbrecht, Germany) and 450 μl are added of a 0.1 M buffered sodium and potassium phosphate solution at pH 7.4 supplemented with 10% of foetal bovine serum (Sera Laboratories International Ltd.) and 0.05% of Tween-20® (Sigma). The mixture is incubated at 37° C. for 1 h in a Thermomixer 5436 incubator (Eppendorf, Hamburg, Germany).
The serum or plasma sample is thawed from −20° C. to ambient temperature (between 20 and 25° C.), repeatedly turning the tube to homogenise its contents before pretreatment. This sample pretreatment variant demonstrates the detection specificity for anti-HCV according to the method object of the invention. It consists in an incubation the purpose of which is to mask the specific anti-HCV antibodies of the sample using the non-specific antibody-antigen peptide bond in order to mask the specific anti-HCV antibodies in the sample and therefore block their binding to the HCV reagent by the immunochemistry reaction described in Example 5. 50 μl of serum or plasma sample are placed in a 1.5 ml polypropylene microtube (Sarsted, Nümbrecht, Germany) and 450 μl are added of a 0.1 M buffered sodium and potassium phosphate solution at pH 7.4 supplemented with 10% of foetal bovine serum (Sera Laboratories International Ltd.) to which 0.05% of Tween-20® (Sigma) are added that do not contain (“no blocking”) or contain (“blocking”) sufficient amounts (between 10 and 1000 μg/ml) of the HCV reagent described in Example 2 (synthetic pentadecapeptide with the sequence of SEQ.ID.NO:1). Another peptide reagent of the HCV core protein (amino acids 21-40 with the sequence shown in
Samples pretreated according to the previous example (100 μl) are added to the wells of reaction matrix; the plate is covered with a transparent sheet (“Plate Sealer”, Perkin Elmer—Wallac, Turku, Finland) and incubated for 1 hour at 37° C. in a Heraeus I-42 incubator. When the incubation has finished withdraw the transparent sheet and wash each well 5 times with 200 μl of washout solution. When the last washout has finished, remove the excess washout solution by turning the plate upside down over absorbent paper.
The conjugated antiserum used in the method object of the invention is a polyclonal anti-human immunoglobulin G (IgG) antiserum obtained from rabbits by immunisation with IgG isolated from normal human sera and conjugated with the horseradish peroxidase enzyme (anti-IgG-HRP; DakoCytomation A/S, Glostrup, Denmark). The conjugated antiserum is supplied as a fluid in a buffered solution of 0.05 mmol/l Tris-HCl, 15 mmol/l NaN3 at pH 7.2 at a concentration of 1 mg/mL. It is kept at 4° C. until use. To prepare the conjugated antisera solution 11 μl of anti-IgG-HRP and 11 ml of blocking agent solution (described in Example 3) are mixed, obtaining a 1:1000 dilution that is optimal for this type of EIA (Harlow D & Lane D. Antibodies: A laboratory manual. Cold Spring Harbor Laboratory, New York; 1988: pp 592). 100 μl of the conjugated antisera solution are added to each well of the reaction in order to detect the antigen-antibody immunochemistry reaction; the plate is covered with a transparent sheet (“Plate Sealer”, Perkin Elmer—Wallac) and incubated for 1 hour at 37° C. in a Heraeus I-42 incubator. When the incubation has finished withdraw the transparent sheet and wash each well 5 times with 200 μl of washout solution. When the last washout has finished, remove the excess washout solution by turning the plate upside down over absorbent paper.
The method object of the invention uses the 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt as a developing solution (ABTS; Pierce, Rockford, Ill., USA). ABTS is a chromogenic substrate of horseradish peroxidase that gives rise to a green coloured product when oxidized. ABTS is supplied as a ready-to-use liquid solution (which does not require subsequent preparation) and is stored at 4° C. until use. The ABTS solution must be brought to room temperature before use (between 20 and 25° C.). The ABTS substrate (100 μl/well) is added to the microplate wells and incubated for 30 minutes in the dark (for which the entire plate is covered, for example, with a sheet of aluminium foil) with gentle stirring in an Atom 85 stirrer (Atom, Barcelona, Spain). Optionally, a 1% n-sodium dodecyl sulphate can be used as a reaction stopper solution (Calbiochem—Biosciences Inc., La Jolla, Calif., USA) (100 μl/well). The reaction is measured in a Whittaker Microplate Reader 2001 (Anthos Labtec Instruments, Salzburg, Austria) at a wavelength of 405 nm with a reference wavelength of 620 nm. The intensity of the green colour depends on the amount of anti-HCV present in the sample analysed.
The samples are obtained from patients diagnosed with HCV infection following the method described in Example 1. The sample is then analysed to detect the presence of anti-HCV using ELISA with the method object of the invention. To do this, the reaction matrix is prepared following the description of example 3 using the reagent of example 2.
The sample (serum in this case) is pre-treated as described in Example 4 and the immunochemistry reaction is performed as in Example 5, and the presence of anti-HCV is determined using ELISA following the methods described above in Examples 6 and 7. The determination is performed in duplicate using as controls the samples of 3 healthy people (negative controls) and 1 patient showing anti-HCV positive results by commercial ELISA (positive control) obtained and processed as described in Examples 1, 4 and 5. The following results are obtained when measuring the reaction:
Patient (female) who presents at the office due to anomalous values of hepatic enzymes. Known causes of liver disease are ruled out, including classic HCV infection (anti-HCV and HCV-RNA not detected in serum by commercial methods). The liver biopsy proves the presence of genotype 1 HCV-RNA, and therefore latent HCV infection is diagnosed and liver lesion is detected (liver cirrhosis with inflammatory activity).
Patient (male) who presents at the office due to anomalous values of hepatic enzymes. Known causes of liver disease are ruled out, including classic HCV infection (anti-HCV and HCV-RNA not detected in serum by commercial methods). The liver biopsy proves the presence of genotype 1b HCV-RNA, and therefore latent HCV infection is diagnosed and a liver lesion is detected (periportal chronic hepatitis with stage 2 fibrosis).
The samples are obtained from patients diagnosed with HCV infection following the method described in Example 1. The sample is then analysed to detect the presence of anti-HCV using ELISA with the method object of the invention. To do this, the reaction matrix is prepared following the description of example 3 using the reagent of example 2. The sample (serum in this case) is pre-treated as described in Example Obis and the immunochemistry reaction is performed as in Example 5, and the presence of anti-HCV is determined using ELISA following the methods described above in Examples 6 and 7. The determination is performed in duplicate using as controls the samples of 3 healthy people (negative controls) and 1 patient showing anti-HCV positive results by commercial ELISA (positive control) obtained and processed as described in Examples 1, 4 and 5. The following results are obtained when measuring the reaction:
The cut-off value between the NEGATIVE and POSITIVE results is determined (test cut-off value) as the addition of the mean value of the 3 negative controls plus five times the standard deviation for the mean value.
The cut-off value for the test is 0.091 absorbance units at 405/620 nm.
The reaction is considered specific if it blocks anti-HCV detection. That is, the absorbance values measured by sample pre-treatment in the presence of the HCV reagent corresponding to SEQ.ID.NO:1 are at least 50% less than when the pretreatment is performed without the HCV reagent. Moreover, the reaction is also considered specific if it does not block anti-HCV detection when pre-treating the sample in the presence of the control reagent described in example Obis; the absorbance values measured decrease less than 10% compared to the mean values measured when pretreating without the HCV reagent. The percentage of anti-HCV detection blocking will be calculated according to following formula:
% blocking=100−100×
(absorbance of sample with HCV reagent)−(absorbance of negative control with HCV reagent)
(absorbance of sample without HCV reagent)−(absorbance of negative control without HCV reagent)
Patient (female) who presents at the office due to anomalous values of hepatic enzymes. Known causes of liver disease are ruled out, including classic HCV infection (anti-HCV and HCV-RNA not detected in serum by commercial methods). The liver biopsy proves the presence of genotype 1 HCV-RNA, and therefore latent HCV infection is diagnosed and liver lesion is detected (liver cirrhosis with inflammatory activity).
Patient (male) who presents at the office due to anomalous values of hepatic enzymes. Known causes of liver disease are ruled out, including classic HCV infection (anti-HCV and HCV-RNA not detected in serum by commercial methods). The liver biopsy proves the presence of genotype 1b HCV-RNA, and therefore latent HCV infection is diagnosed and reactive changes are detected in the liver (minimum lesion).
Patient (female) who presents at the office due to anomalous values of hepatic enzymes. Classic HCV infection is diagnosed (anti-HCV and HCV-RNA detectable in serum using commercial methods). The liver biopsy proves the presence of genotype 1b HCV-RNA and liver lesion (active chronic hepatitis with stage 1 liver fibrosis).
This allows measuring the amount of anti-HCV antibody present in the sample to be analysed. This measurement can be related to clinical, histopathological, virological or other characteristics and with the progression of HCV infection, either latent or classic, and the follow-up following antiviral treatment. The samples are obtained from patients diagnosed with HCV infection following the method described in Example 1. The sample is then analysed to detect the presence of anti-HCV using ELISA with the method object of the invention. To do this, the reaction matrix is prepared following the description of example 3 using the reagent of example 2. The sample is pretreated (serum in this case) as in Example 4. The pretreated sample, which is diluted to 1:10, is diluted in a twofold dilution series, i.e., 1:20, 1:40, 1:80, etc.; the immunochemistry reaction is performed as in Example 5 and the presence of anti-HCV is detected by ELISA, following the methods described above in Examples 6 and 7. The determination is performed in duplicate using as controls the samples of 3 healthy people (negative controls) and 1 patient showing anti-HCV positive results by commercial ELISA (positive control) obtained and processed as described in Examples 1, 4 and 5. The following results are obtained when measuring the reaction:
Patient (male) who presents at the office due to anomalous values of hepatic enzymes. Known causes of liver disease are ruled out, including classic HCV infection (anti-HCV and HCV-RNA not detected in serum by commercial methods). The liver biopsy proves the presence of genotype 1b HCV-RNA, and therefore latent HCV infection is diagnosed and steatosis is observed with minimum inflammatory changes in the liver. The following average results are obtained in absorbance units at 405/620 nm when measuring the reaction:
The serum analysed contains anti-HCV antibodies at a concentration of 1:160.
Patient (female) who presents at the office due to anomalous values of hepatic enzymes. Classic HCV infection is diagnosed (anti-HCV and HCV-RNA detectable in serum using commercial methods). The liver biopsy proves the presence of genotype 1a HCV-RNA and liver lesion (periportal hepatitis with septal fibrosis). The following average results are obtained in absorbance units at 405/620 nm when measuring the reaction:
The serum analysed contains anti-HCV antibodies at a concentration of 1:2560.
This allows knowing the type and isotype of the immunoglobulin (IG) of the anti-HCV antibody (type: IgA, IgG, IgM; IgG isotype: IgG1, IgG2, etc.) present in the sample to be analysed. This measurement can be related to clinical, histopathological, virological or other characteristics and with the progression of HCV infection, either latent or classic, and the follow-up following antiviral treatment. The samples are obtained from patients diagnosed with HCV infection following the method described in Example 1. The sample is then analysed to detect the presence of anti-HCV using ELISA with the method object of the invention. To do this, the reaction matrix is prepared following the description of example 3 using the reagent of example 2. The sample (in this case serum) is pre-treated as described in Example 4 and the immunochemistry reaction is performed as in Example 5, and the presence of anti-HCV is determined using ELISA following the methods described above in Examples 6 and 7. The determination is performed in duplicate using as controls the samples of 3 healthy people (negative controls) and 1 patient showing anti-HCV positive results by commercial ELISA (positive control) obtained and processed as described in Examples 1, 4 and 5. The reagent of example 6 (anti-IgG-HRP) is replaced by a specific reagent of the same type (e.g.: anti-IgM-HRP) or isotype (e.g.: anti-IgG1-HRP) as the antibody to be detected. The following results are obtained when measuring the reaction:
Patient (male) who presents at the office due to anomalous values of hepatic enzymes. Known causes of liver disease are ruled out, including classic HCV infection (anti-HCV and HCV-RNA not detected in serum by commercial methods). The liver biopsy proves the presence of genotype 1b HCV-RNA, and therefore latent HCV infection is diagnosed and minimal liver lesions are observed. The following average results are obtained in absorbance units at 405/620 nm when measuring the reaction:
The serum analysed contains anti-HCV antibodies of type IgG and isotype IgG1.
Patient (female) who presents at the office due to anomalous values of hepatic enzymes. Classic HCV infection is diagnosed (anti-HCV and HCV-RNA detectable in serum using commercial methods). The liver biopsy proves the presence of genotype 1b HCV-RNA and liver lesion (active chronic hepatitis with stage 1 liver fibrosis). The following average results are obtained in absorbance units at 405/620 nm when measuring the reaction:
The serum analysed contains anti-HCV antibodies of type IgG and isotypes IgG1 and IgG3.
The samples are obtained from patients undergoing haemodialysis with latent HCV infection following the method described in Example 1. The sample is then analysed to detect the presence of anti-HCV using ELISA with the method object of the invention. To do this, the reaction matrix is prepared following the description of example 3 using the reagent of example 2. The sample (plasma in this case) is pre-treated as described in Example 4 and the immunochemistry reaction is performed as in Example 5, and the presence of anti-HCV is determined using ELISA following the methods described above in Examples 6 and 7. The determination is performed in duplicate using as controls the samples of 3 healthy people (negative controls) and 1 patient showing anti-HCV positive results by commercial ELISA (positive control) obtained and processed as described in Examples 1, 4 and 5. The following results are obtained when measuring the reaction:
The cut-off value for the test is 0.091 absorbance units at 405/620 nm.
A patient (male) who due to his chronic kidney disease has been receiving haemodialysis for over 12 months. He receives analytical controls regularly and shows anomalous values of hepatic enzymes.
A patient (male) who due to his chronic kidney disease (CKD) has been receiving haemodialysis for over 12 months. He receives blood transfusions due to his CKD-related anaemia. He presents anomalous values for liver enzymes in a laboratory test.
The samples are obtained from people with potential risk of latent HCV infection (e.g., relatives of patients with latent HCV infection) following the method described in Example 1. The sample is then analysed to detect the presence of anti-HCV using ELISA with the method object of the invention. To do this, the reaction matrix is prepared following the description of example 3 using the reagent of example 2. The sample (serum in this case) is pre-treated as described in Example 4 and the immunochemistry reaction is performed as in Example 5, and the presence of anti-HCV is determined using ELISA following the methods described above in Examples 6 and 7. The determination is performed in duplicate using as controls the samples of 3 healthy people (negative controls) and 1 patient showing anti-HCV positive results by commercial ELISA (positive control) obtained and processed as described in Examples 1, 4 and 5. The following results are obtained when measuring the reaction:
Relative (sister) of patient (male) diagnosed with genotype 1b latent HCV infection and mild chronic lobular hepatitis mild, who presents at the office for medical examination and laboratory tests.
Relative (spouse) of patient (male) diagnosed with genotype latent HCV infection, who presents at the office for medical examination and laboratory tests.
Relative (daughter) of patient (female) diagnosed with cirrhosis of the liver due to classic HCV infection (anti-HCV and HCV-RNA detected in serum using commercial methods), who presents at the office for medical examination and analytical tests. Has normal values for liver enzymes and gives non-conclusive result for classic HCV infection (undetermined anti-HCV and HCV-RNA not detected in serum using commercial methods). She is diagnosed as an anti-HCV carrier. Liver biopsy shows mild steatosis and the presence of genotype 1 HCV-RNA, and she is therefore diagnosed with HCV infection.
The determination of anti-HCV is repeated on a subsequent sample of serum and gives a negative using commercial methods.
The samples are obtained from patients diagnosed with HCV infection following the method described in Example 1. The sample is then analysed to detect the presence of anti-HCV using ELISA with the method object of the invention. To do this, the reaction matrix is prepared following the description of example 3 using the reagent of example 2. The sample (in this case serum) is pre-treated as described in Example 4 and the immunochemistry reaction is performed as in Example 5, and the presence of anti-HCV is determined using ELISA following the methods described above in Examples 6 and 7. The determination is performed in duplicate using as controls the samples of 3 healthy people (negative controls) and 1 patient showing anti-HCV positive results by commercial ELISA (positive control) obtained and processed as described in Examples 1, 4 and 5. The following results are obtained when measuring the reaction:
Patient (female) who presents at the office due to anomalous values of hepatic enzymes. Classic HCV infection is diagnosed (anti-HCV and HCV-RNA detectable in serum using commercial methods). The liver biopsy proves the presence of genotype 3a HCV-RNA and liver lesion (active chronic hepatitis without liver fibrosis).
Patient (male) who presents at the office due to anomalous values of hepatic enzymes. Classic HCV infection is diagnosed (anti-HCV and HCV-RNA detectable in serum using commercial methods). The liver biopsy proves the presence of genotype 4 HCV-RNA and liver lesion (active chronic hepatitis with stage 1 liver fibrosis).
The samples are obtained from patients diagnosed with HCV infection following the method described in Example 1. The sample is then analysed to detect the presence of anti-HCV using ELISA with the method object of the invention. To do this, prepare the reaction matrix as described in Example 3, using the reagent corresponding to SEQ.ID.NO.:3. The sample (in this case serum) is pre-treated as described in Example and the immunochemistry reaction is performed as in Example 5, and the presence of anti-HCV is determined using ELISA following the methods described above in Examples 6 and 7. The determination is performed in duplicate using as controls the samples of 3 healthy people (negative controls) and 1 patient showing anti-HCV positive results by commercial ELISA (positive control) obtained and processed as described in Examples 1, 4 and 5. The following results are obtained when measuring the reaction:
Patient (male) who presents at the office due to anomalous values of hepatic enzymes. Known causes of liver disease are ruled out, including classic HCV infection (anti-HCV and HCV-RNA not detected in serum by commercial methods). The liver biopsy proves the presence of genotype 1b HCV-RNA, and therefore latent HCV infection is diagnosed and reactive changes are detected in the liver (minimum lesion). The serum from patient No. 17 gives a NEGATIVE result when the determination of anti-core HCV IgG antibodies is performed using the reagent described in Example 2.
Patient (male) who presents at the office due to anomalous values of hepatic enzymes. Known causes of liver disease are ruled out, including classic HCV infection (anti-HCV and HCV-RNA not detected in serum by commercial methods). The liver biopsy proves the presence of genotype 1b HCV-RNA, and therefore latent HCV infection is diagnosed and a liver lesion is detected (active chronic hepatitis with stage 4 liver fibrosis). The serum from patient No. 18 gives a POSITIVE result when the determination of anti-core HCV IgG antibodies is performed using the reagent described in Example 2.
Patient (female) who presents at the office due to anomalous values of hepatic enzymes. Classic HCV infection is diagnosed (anti-HCV and HCV-RNA detectable in serum using commercial methods). The liver biopsy proves the presence of genotype 3a HCV-RNA and liver lesion (active chronic hepatitis with stage 1 liver fibrosis).
| Number | Date | Country | Kind |
|---|---|---|---|
| P200800493 | Feb 2008 | ES | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/ES2009/000019 | 1/16/2009 | WO | 00 | 11/22/2010 |
